

CITATION REPORT

List of articles citing

Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group

DOI: 10.1016/s0002-9149(98)00692-4
American Journal of Cardiology, 1998, 82, 1489-95.

Source: <https://exaly.com/paper-pdf/28951545/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
261	Is there a Place for LDL-apheresis in Non-Homozygous Patients?. 1999 , 22, 723-725		3
260	Selective therapeutic extraction of plasma constituents, revisited. 1999 , 39, 671-3		7
259	Drug treatment of lipid disorders. 1999 , 341, 498-511		718
258	Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). <i>Atherosclerosis</i> , 1999 , 144, 409-17	3.1	78
257	Non-pharmacological lowering of low-density lipoprotein by apheresis and surgical techniques. <i>Current Opinion in Lipidology</i> , 1999 , 10, 575-9	4.4	3
256	Therapeutic effects of LDL apheresis in the prevention of atherosclerosis. <i>Current Opinion in Lipidology</i> , 1999 , 10, 401-6	4.4	17
255	Coronary artery bypass surgery with arterial grafts in familial hypercholesterolemia. 2000 , 119, 1008-13; discussion 1013-4		7
254	Incorporation of low-density lipoprotein apheresis into the treatment program of patients with severe hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2000 , 2, 308-13	6	16
253	Genetic underpinnings of LDL size and density: a role for hepatic lipase?. 2000 , 71, 1390-1		14
252	Intraindividual Comparison of the Impact of two Selective Apheresis Methods (DALI and HELP) on the Coagulation System. 2000 , 23, 199-206		28
251	Management of hypercholesterolemia. 2000 , 84, 23-42		45
250	Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2000 , 151, 493-9	3.1	47
249	Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia. 2001 , 76, 1039-46		26
248	MANAGEMENT OF HYPERCHOLESTEROLEMIA. 2001 , 19, 295-310		1
247	Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses. <i>Current Atherosclerosis Reports</i> , 2001 , 3, 156-62	6	7
246	Dyslipidemia. 2001 , 3, 347-357		1
245	Apheresis technology for prevention and regression of atherosclerosis. <i>Therapeutic Apheresis and Dialysis</i> , 2001 , 5, 221-5	1.9	23

244	Effects of low-density lipoprotein apheresis on coronary and carotid atherosclerosis and diabetic scleredema in patients with severe hypercholesterolemia. <i>Therapeutic Apheresis and Dialysis</i> , 2001 , 5, 244-51	1.9	11
243	Beneficial effect of aggressive low-density lipoprotein apheresis in a familial hypercholesterolemic patient with severe diabetic scleredema. <i>Therapeutic Apheresis and Dialysis</i> , 2001 , 5, 506-12	1.9	2
242	Current topics on low-density lipoprotein apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2001 , 5, 293-300	1.9	17
241	Effect of extracorporeal low-density lipoprotein elimination on circulating cell adhesion molecules in patients with hypercholesterolemia. <i>American Journal of Cardiology</i> , 2001 , 87, 1111-3, A9	3	13
240	Frequency of subacute resumption of isthmus conduction after ablation of atrial flutter. <i>American Journal of Cardiology</i> , 2001 , 87, 1113-6, A9	3	6
239	Low-density lipoprotein apheresis in a patient aged 3.5 years. 2001 , 90, 694-701		20
238	Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). 2002 , 40, 220-7		137
237	Coronary plaque regression: role of low density lipoprotein-apheresis. 2002 , 40, 228-30		10
236	Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. 2002 , 321, 107-12		24
235	Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. 2002 , 25, 1180-8		39
234	Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis. <i>Journal of Clinical Apheresis</i> , 2002 , 17, 161-9	3.2	37
233	Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components. 2002 , 76, 279-83		15
232	Familial Hypercholesterolemia. 2002 , 4, 121-128		4
231	Comparison of two filter combinations for low-density lipoprotein apheresis by membrane differential filtration: a prospective crossover controlled clinical study. 2002 , 26, 371-7		4
230	In vitro evaluation of dextran sulfate cellulose beads for whole blood infusion low-density lipoprotein-hemoperfusion. 2002 , 6, 365-71		27
229	Meaning of low-density lipoprotein-apheresis for hypercholesterolemic patients at high risk for recurrence of coronary heart disease. 2002 , 6, 372-80		4
228	What's new in lipid management?. 2003 , 23, 34S-40S		2
227	Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study. <i>Journal of Clinical Apheresis</i> , 2003 , 18, 157-66	3.2	10

226	Blood purification therapies using dextran sulfate cellulose columns Liposorber and Selesorb. <i>Therapeutic Apheresis and Dialysis</i> , 2003 , 7, 73-7	1.9	20
225	From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2003 , 7, 350-8	1.9	31
224	Indication of low-density lipoprotein apheresis in severe hypercholesterolemia and its atherosclerotic vascular complications: dextran sulfate cellulose low-density lipoprotein apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2003 , 7, 345-9	1.9	8
223	Brief history of low-density lipoprotein apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2003 , 7, 378-81	1.9	4
222	Low-density lipoprotein apheresis: an overview. <i>Therapeutic Apheresis and Dialysis</i> , 2003 , 7, 382-90	1.9	56
221	Long-term effect of low-density lipoprotein apheresis in patients with heterozygous familial hypercholesterolemia. <i>Therapeutic Apheresis and Dialysis</i> , 2003 , 7, 402-7	1.9	12
220	Low-density lipoprotein apheresis in the prevention of recurrent coronary heart disease: a review. <i>Therapeutic Apheresis and Dialysis</i> , 2003 , 7, 408-12	1.9	14
219	Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. 2003 , 27, 1116-22		48
218	LDL apheresis. <i>Atherosclerosis</i> , 2003 , 167, 1-13	3.1	154
217	Familial hypercholesterolemia--improving treatment and meeting guidelines. 2003 , 89, 13-23		47
216	[LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy]. 2003 , 92, III6-27		0
215	Effects of LDL apheresis and vitamin E-modified membrane on carotid atherosclerosis in hemodialyzed patients with arteriosclerosis obliterans. 2003 , 26, 185-91		21
214	Effect of adsorbent of Riposorber, a cellulose microparticle with immobilized dextran sulfate, on the serum complement system. 2003 , 14, 1255-67		4
213	Effectiveness of long-term heparin-induced extracorporeal LDL precipitation (HELP) in improving coronary calcifications. 2003 , 26, 252-5		9
212	LDL-apheresis in acute anterior ischemic optic neuropathy. 2004 , 27, 337-41		17
211	Retrospective comparison of 5 different methods for long-term LDL-apheresis in 20 patients between 1986 and 2001. 2004 , 27, 137-48		18
210	State of the art of low-density lipoprotein apheresis in the year 2003. <i>Therapeutic Apheresis and Dialysis</i> , 2004 , 8, 76-9	1.9	32
209	Evaluation of improved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2004 , 8, 383-9	1.9	14

208	Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. <i>Journal of Clinical Apheresis</i> , 2004 , 19, 11-6	3.2	29
207	In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis?. 2004 , 30, 213-20		4
206	Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia. 2004 , 30, 233-43		12
205	Lipidfiltration--safe and effective methodology to perform lipid-apheresis. 2004 , 30, 245-54		49
204	Treatment of hyperlipidemia in cardiac transplant recipients. 2004 , 148, 200-10		47
203	Long-term reduction of C-reactive protein concentration by regular LDL apheresis. <i>Atherosclerosis</i> , 2004 , 174, 151-6	3.1	32
202	Hypercholesterolemia and LDL apheresis. 2005 , 28, 1025-31		11
201	[Need to change the direction of cholesterol-related medication--a problem of great urgency]. 2005 , 125, 833-52		0
200	Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia (FH). 2005 , 69, 515-20		14
199	Therapeutic apheresis--state of the art in the year 2005. <i>Therapeutic Apheresis and Dialysis</i> , 2005 , 9, 459-68		66
198	Role of low-density lipoprotein apheresis. <i>American Journal of Cardiology</i> , 2005 , 96, 67E-69E	3	15
197	Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. <i>Journal of Clinical Apheresis</i> , 2005 , 20, 252-5	3.2	45
196	Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy. 2005 , 46, 833-43		31
195	Photoelectric plasma-leakage monitoring apparatus. 2005 , 41, 517		
194	Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein. 2005 , 358, 192-5		21
193	Optimization of the therapeutic procedure during LDL-apheresis--a computerized model. 2005 , 32, 149-56		2
192	New therapies for familial hypercholesterolemia. 2006 , 16, 349-361		
191	A systematic review of LDL apheresis in the treatment of cardiovascular disease. <i>Atherosclerosis</i> , 2006 , 189, 31-8	3.1	68

190	LDL-apheresis therapy: current therapeutic practice and potential future use. 2006 , 1, 299-308		10
189	LDL Apheresis: an effective and safe treatment for refractory hypercholesterolemia. 2002 , 20, 271-80		16
188	Low-density lipoprotein apheresis therapy with a direct hemoperfusion column: a Japanese multicenter clinical trial. <i>Therapeutic Apheresis and Dialysis</i> , 2006 , 10, 32-41	1.9	14
187	Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines. <i>Therapeutic Apheresis and Dialysis</i> , 2006 , 10, 305-15	1.9	30
186	LDL-apheresis therapy. 2006 , 8, 282-8		24
185	Is the efficacy of LDL apheresis in ischemic optic neuropathy linked to a reduction in endothelial activation markers?. 2006 , 24, 405-12		11
184	[Effects of LDL-apheresis--more than reduction of cholesterol?]. 2007 , 132, 575-8		5
183	What's going on in LDL apheresis. 2007 , 37, 213-21		5
182	Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. 2007 , 356, 148-56		438
181	Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance characteristics with DALI and Lipidfiltration. <i>Journal of Clinical Apheresis</i> , 2007 , 22, 215-23	3.2	23
180	Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms. <i>Journal of Clinical Apheresis</i> , 2007 , 22, 287-91	3.2	4
179	LDL-apheresis: indications and clinical experience in a tertiary cardiac centre. 2007 , 61, 1834-42		9
178	Low-density lipoprotein apheresis in a patient aged 3.5 years. 2007 , 90, 694-701		1
177	Hypocholesterolemic and hepatoprotective effects of flaxseed chutney: Evidence from animal studies. 2007 , 22, 117-21		20
176	Lipid apheresis applications in childhood: experience in the University Hospital of Gazi. 2008 , 39, 235-40		3
175	A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2008 , 197, 400-6	3.1	71
174	Recommendations for the use of LDL apheresis. <i>Atherosclerosis</i> , 2008 , 198, 247-55	3.1	219
173	White matter brain lesions in midlife familial hypercholesterolemic patients at 3-Tesla magnetic resonance imaging. 2008 , 49, 184-9		7

172	Comparison of different LDL apheresis methods. 2008 , 6, 629-39		35
171	Macroporous poly(vinyl alcohol) microspheres bearing phosphate groups as a new adsorbent for low-density lipoprotein apheresis. 2009 , 4, 065007		8
170	Association of ApoE and HDL-C with cardiovascular and cerebrovascular disease: potential benefits of LDL-apheresis therapy. 2009 , 4, 311-329		4
169	Long-term LDL apheresis does not stably improve hemorheology in hypercholesterolemic patients with coronary artery disease. 2009 , 41, 137-42		6
168	Homozygous familial hypercholesterolemia: long term clinical course and plasma exchange therapy for two individual patients and review of the literature. <i>Journal of Clinical Apheresis</i> , 2009 , 24, 219-24	3.2	18
167	Different inflammatory responses induced by three LDL-lowering apheresis columns. <i>Journal of Clinical Apheresis</i> , 2009 , 24, 247-53	3.2	32
166	Low-density lipoprotein apheresis as a treatment option for hyperlipidemia. 2009 , 11, 279-88		19
165	[LDL apheresis for the treatment of familial hypercholesterolemia. A systematic review]. 2009 , 104, 1-9		2
164	Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. 2009 , 49, 1461-70		25
163	Acute effects of lipid apheresis on human serum lipodome. <i>Atherosclerosis Supplements</i> , 2009 , 10, 27-33	1.7	15
162	Pleiotropic effects of LDL apheresis. <i>Atherosclerosis Supplements</i> , 2009 , 10, 53-5	1.7	14
161	The German Lipid Apheresis Registry - remaining to be established. <i>Atherosclerosis Supplements</i> , 2009 , 10, 59-61	1.7	7
160	Lipid apheresis and rheopheresis for treatment of peripheral arterial disease. <i>Atherosclerosis Supplements</i> , 2009 , 10, 62-9	1.7	2
159	Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany's largest apheresis center). <i>Atherosclerosis Supplements</i> , 2009 , 10, 137-41	1.7	10
158	Marked aortic valve stenosis progression after receiving long-term aggressive cholesterol-lowering therapy using low-density lipoprotein apheresis in a patient with familial hypercholesterolemia. 2009 , 73, 963-6		103
157	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. <i>Current Opinion in Lipidology</i> , 2010 , 21, 492-8	4.4	77
156	Atorvastatin: a review of its pharmacological properties and use in familial hypercholesterolemia. 2010 , 5, 615-625		7
155	Hematologic and hemostatic changes induced by different columns during LDL apheresis. <i>Journal of Clinical Apheresis</i> , 2010 , 25, 294-300	3.2	17

154	Comparison of different low density lipoprotein apheresis machines on brain natriuretic Peptide levels in patients with familial hypercholesterolemia. <i>Therapeutic Apheresis and Dialysis</i> , 2010 , 14, 74-8	1.9	2
153	Retrospective analysis of long-term lipid apheresis at a single center. <i>Therapeutic Apheresis and Dialysis</i> , 2010 , 14, 143-52	1.9	38
152	Low-density lipoprotein apheresis by membrane differential filtration (cascade filtration) via arteriovenous fistula performed in children with familial hypercholesterolemia. <i>Therapeutic Apheresis and Dialysis</i> , 2010 , 14, 87-92	1.9	2
151	Encouraging appropriate treatment for familial hypercholesterolemia. 2010 , 5, 339-354		9
150	[Advances in cholesterol-lowering interventions]. 2010 , 57, 210-9		8
149	LDL apheresis improves deranged cardioagal modulation in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2010 , 213, 212-7	3.1	9
148	Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011 , 5, S18-29	4.9	90
147	Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011 , 5, S38-45	4.9	102
146	Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia. 2011 , 56, 842-9		36
145	Effects of selective H.E.L.P. LDL-apheresis on plasma inflammatory markers concentration in severe dyslipidemia: Implication for anti-inflammatory response. 2011 , 56, 850-4		15
144	Familial hypercholesterolaemia: a model of care for Australasia. <i>Atherosclerosis Supplements</i> , 2011 , 12, 221-63	1.7	153
143	Role of apheresis in the management of familial hypercholesterolemia and elevated Lp(a) levels. 2011 , 6, 523-538		2
142	Lipid apheresis, indications, and principles. <i>Journal of Clinical Apheresis</i> , 2011 , 26, 269-75	3.2	39
141	Conventional apheresis therapies: a review. <i>Journal of Clinical Apheresis</i> , 2011 , 26, 230-8	3.2	82
140	The blood compatibilities of blood purification membranes and other materials developed in Japan. 2011 , 2011, 375390		8
139	Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. 2011 , 124, 2202-7		235
138	Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. 2012 , 53, 1670-8		43
137	Changes in Lipids and Lipoproteins after Selective LDL Apheresis (7-Year Experience). 2012 , 2012, 976578		8

136	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. 2012 , 380, 1995-2006		276
135	Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. 2012 , 380, 2007-17		327
134	Low-density lipoprotein apheresis: principles and indications. 2012 , 25, 145-51		7
133	A critical review on the use of lipid apheresis and rheopheresis for treatment of peripheral arterial disease and the diabetic foot syndrome. 2012 , 25, 220-7		16
132	Characteristics of carotid atherosclerotic plaques of chronic lipid apheresis patients as assessed by in vivo high-resolution CMR--a comparative analysis. 2012 , 14, 80		13
131	Guidelines for the management of familial hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012 , 19, 1043-60	4	126
130	LDL-apheresis: technical and clinical aspects. 2012 , 2012, 314283		47
129	Treatment of familial hypercholesterolemia: is there a need beyond statin therapy?. <i>Current Atherosclerosis Reports</i> , 2012 , 14, 11-6	6	21
128	Efficacy and safety of mipomersen sodium (Kynamro). 2013 , 12, 569-79		21
127	Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. <i>Journal of Clinical Apheresis</i> , 2013 , 28, 145-284	3.2	455
126	The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. <i>Atherosclerosis Supplements</i> , 2013 , 14, 67-70	1.7	48
125	[Low-density lipoprotein apheresis in familial hypercholesterolemia resistant to intensive medical treatment]. 2013 , 140, 207-10		2
124	[Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: guidelines from the New French Society of Atherosclerosis (NSFA)]. 2013 , 42, 930-50		19
123	Low-density lipoprotein cholesterol: how low can we go?. 2013 , 13, 225-32		8
122	Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels. <i>Atherosclerosis Supplements</i> , 2013 , 14, 129-34	1.7	3
121	Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. <i>Atherosclerosis Supplements</i> , 2013 , 14, 39-44	1.7	45
120	Lipoprotein apheresis: state of the art and novelties. <i>Atherosclerosis Supplements</i> , 2013 , 14, 19-27	1.7	56
119	Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells. <i>Atherosclerosis Supplements</i> , 2013 , 14, 107-13	1.7	16

118	Factors inducing cardiovascular events in patients treated by lipoprotein apheresis. <i>Atherosclerosis Supplements</i> , 2013 , 14, 45-50	1.7	8
117	Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease. <i>Atherosclerosis Supplements</i> , 2013 , 14, 135-41	1.7	4
116	Lipoprotein apheresis--more than just cholesterol reduction?. <i>Atherosclerosis Supplements</i> , 2013 , 14, 29-32	1.7	11
115	Lipoprotein apheresis standard for apheresis competence centers--an updated synthesis and amendment to pre-existing standards. <i>Atherosclerosis Supplements</i> , 2013 , 14, 57-65	1.7	11
114	Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis. <i>Journal of Clinical Lipidology</i> , 2013 , 7, S21-6	4.9	16
113	Lipoprotein apheresis for the treatment of familial hypercholesterolemia. 2013 , 8, 573-586		4
112	Lipoprotein apheresis: an update. 2013 , 8, 693-705		24
111	Schwere, asymptomatische Hypercholesterinämie im jungen Lebensalter. <i>CardioVasc</i> , 2013 , 13, 39-44	0	
110	Current challenges in the management of patients with familial hypercholesterolemia. 2013 , 8, 217-229		
109	Steps Beyond Diet and Drug Therapy for Severe Hypercholesterolemia. 2013 , 454-462		
108	Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease. <i>Therapeutic Apheresis and Dialysis</i> , 2013 , 17, 185-92	1.9	16
107	Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. 2013 , 22, 1411-23		18
106	Lipidapherese. <i>CardioVasc</i> , 2013 , 13, 48-52	0	2
105	Familial hypercholesterolaemia presenting with coronary artery disease in a young patient. 2013 , 2013,		1
104	THE ROLE OF LIPOTROPIC THERAPY IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE BEFORE AND AFTER CORONARY REVASCULARIZATION. 2013 , 9, 564-569		
103	Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia. 2014 , 55, 2064-72		27
102	Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design. <i>Journal of Clinical Apheresis</i> , 2014 , 29, 97-106	3.2	6
101	Removal of biological response modifiers associated with platelet transfusion reactions by columns containing adsorption beads. 2014 , 54, 1790-7		7

100	National Lipid Association Annual Summary of Clinical Lipidology 2015. <i>Journal of Clinical Lipidology</i> , 2014 , 8, S1-36	4.9	56
99	Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2014 , 18, 93-102	1.9	23
98	Clearance of plasma proprotein convertase subtilisin/kexin 9 by low-density lipoprotein apheresis. 2014 , 115, e3-4		6
97	Familial hypercholesterolemia: A review. 2014 , 7, 107-17		39
96	Preventing early cardiovascular death in patients with familial hypercholesterolemia. 2014 , 114, 99-108		16
95	Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. 2014 , 28, 387-403		24
94	Novel treatments for familial hypercholesterolemia: pharmacogenetics at work. 2014 , 34, 961-72		7
93	Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives. <i>Current Opinion in Lipidology</i> , 2015 , 26, 200-9	4.4	44
92	The genetics of familial hypercholesterolemia and emerging therapies. 2015 , 8, 27-36		28
91	[Treating hypercholesterolemia - when and how]. 2015 , 140, 1490-3		
90	The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations. <i>Current Atherosclerosis Reports</i> , 2015 , 17, 467	6	16
89	Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. <i>Current Atherosclerosis Reports</i> , 2015 , 17, 465	6	40
88	Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden. <i>Atherosclerosis Supplements</i> , 2015 , 18, 45-52	1.7	17
87	Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. <i>Atherosclerosis Supplements</i> , 2015 , 18, 154-62	1.7	45
86	The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience. <i>Atherosclerosis Supplements</i> , 2015 , 18, 268-72	1.7	8
85	Recommendations for the management of patients with familial hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2015 , 17, 473	6	9
84	Lipoprotein apheresis. 2015 , 33, 197-208		19
83	A Case-Based Guide to Clinical Endocrinology. 2015 ,		

82	Lipoprotein apheresis. <i>Current Atherosclerosis Reports</i> , 2015 , 17, 39	6	9
81	Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. 2015 , 127, 655-63		12
80	Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease. 2016 ,		0
79	Lipoprotein apheresis in the management of severe hypercholesterolemia and of elevation of lipoprotein(a): current perspectives and patient selection. 2016 , 9, 349-360		15
78	Single Low-Density Lipoprotein Apheresis Does Not Improve Vascular Endothelial Function in Chronically Treated Hypercholesterolemic Patients. 2016 , 2016, 4613202		6
77	Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	49
76	Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia. <i>Journal of Clinical Apheresis</i> , 2016 , 31, 359-67	3.2	12
75	Cholesterol-lowering pattern affects the progression of atherosclerosis in apolipoprotein E deficient mice. 2016 , 132, 271-274		4
74	Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1188-94	4.9	12
73	Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 970-986	4.9	22
72	Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1011-1021	4.9	82
71	Effects of Liver Transplantation on Lipids and Cardiovascular Disease in Children With Homozygous Familial Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2016 , 118, 504-10	3	15
70	Lipoproteinapherese. 2016 , 10, 187-198		
69	LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 273-82	4.9	27
68	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. 2016 , 4, 850-61		215
67	[Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia]. 2016 , 57, 511-6		
66	Lipoprotein Apheresis. 2016 , 45, 39-54		18
65	National Lipid Association Annual Summary of Clinical Lipidology 2016. <i>Journal of Clinical Lipidology</i> , 2016 , 10, S1-43	4.9	74

64 [PCSK9 inhibitors : Current clinical relevance]. **2017**, 58, 196-201

63 LDL apheresis in Japan. **2017**, 56, 677-681

5

62 Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?. *Atherosclerosis Supplements*, **2017**, 30, 44-49

1.7 5

61 Long-term follow-up of circulating oxidative stress markers in patients undergoing lipoprotein apheresis by Direct Adsorption of Lipids (DALI). *Atherosclerosis Supplements*, **2017**, 30, 115-121

1.7 4

60 History of lipidology and lipoprotein apheresis. *Atherosclerosis Supplements*, **2017**, 30, 1-8

1.7 16

59 H.E.L.P apheresis exerts long term effects on the capacity of circulating proangiogenic cells. *Atherosclerosis Supplements*, **2017**, 30, 232-237

1.7

58 LDL apheresis improves coronary flow reserve on the left anterior descending artery in patients with familial hypercholesterolemia and chronic ischemic heart disease. *Atherosclerosis Supplements*, **2017**, 30, 135-140

1.7 5

57 Cardiovascular Complications of Familial Hypercholesterolemia and Its Novel Therapeutics. *Health Evaluation and Promotion*, **2017**, 44, 846-853

0.1

56 Long-term Low-density Lipoprotein Apheresis in a Patient with Refractory Idiopathic Membranous Glomerulonephritis. *Internal Medicine*, **2017**, 56, 1543-1547

1.1 3

55 Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab. *Internal Medicine*, **2017**, 56, 1531-1535

1

54 Familial Hypercholesterolemia. **2018**, 285-297

53 Vascular access in lipoprotein apheresis: a retrospective analysis from the UK's largest lipoprotein apheresis centre. *Journal of Vascular Access*, **2018**, 19, 52-57

1.8 5

52 Apheresis to Mitigate Atherosclerotic Vascular Disease. *American Journal of Hypertension*, **2018**, 31, 945-949

1

51 Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients. *Journal of Cardiovascular Development and Disease*, **2018**, 5,

4.2 20

50 Lipoproteinapherese im Langzeitverlauf. *CardioVasc*, **2019**, 19, 22-24

0

49 Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017. *Atherosclerosis*, **2019**, 290, 44-51

3.1 15

48 Familial Hypercholesterolemia and Lipoprotein Apheresis. *Journal of Atherosclerosis and Thrombosis*, **2019**, 26, 679-687

4 19

47 Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. *Journal of Clinical Apheresis*, **2019**, 34, 171-354

3.2 45

46	Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry). <i>Journal of Clinical Lipidology</i> , 2019 , 13, 455-467	4.9	9
45	Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?. <i>Atherosclerosis Supplements</i> , 2019 , 40, 23-29	1.7	2
44	Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2019 , 8, e013225	6	44
43	Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis. <i>Atherosclerosis Supplements</i> , 2019 , 40, 38-43	1.7	4
42	Behandlungsoptionen bei schweren Hypercholesterinämien. <i>CardioVasc</i> , 2019 , 19, 31-34	0	1
41	Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). <i>Pathology</i> , 2019 , 51, 227-232	1.6	15
40	Plaque Regression and Endothelial Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER). <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008933	6	1
39	[Hypercholesterolemia - the way to lower LDL-C MMW Fortschritte Der Medizin, 2020 , 162, 36-42	0	1
38	Mental status and physical activity in patients with homozygous familial hypercholesterolemia: A subgroup analysis of a nationwide survey (A-HIT1 registry). <i>Journal of Clinical Lipidology</i> , 2020 , 14, 361-370.e2	4.9	2
37	LDL Apheresis and Lp (a) Apheresis: A Clinician's Perspective. <i>Current Atherosclerosis Reports</i> , 2021 , 23, 15	6	6
36	Lipoprotein apheresis efficacy and challenges: single center experience. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 , 44, 56-56	1.6	1
35	Familial hypercholesterolemia in Southeast and East Asia. <i>American Journal of Preventive Cardiology</i> , 2021 , 6, 100157	1.9	2
34	Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021 , 117, 782-844	1.2	1
33	Use of apheresis in the age of new therapies for familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2021 , 32, 363-369	4.4	0
32	Just not cosmesis! Role of low-density lipoprotein apheresis in familial hypercholesterolemia: Experience at a newly developed tertiary care institution in Northern India. <i>Asian Journal of Transfusion Science</i> , 2021 , 15, 104-108	0.5	
31	Pediatric Therapeutic Apheresis. 2012 , 775-796		2
30	Low-Density Lipoprotein (LDL) Apheresis. <i>Contemporary Endocrinology</i> , 2015 , 483-497	0.3	1
29	Therapeutic Options for Homozygous Familial Hypercholesterolemia: The Role of Lomitapide. <i>Current Medicinal Chemistry</i> , 2020 , 27, 3773-3783	4.3	2

28	The Italian Consensus Conferences on low density lipoprotein-cholesterol apheresis. <i>Blood Transfusion</i> , 2017 , 15, 1-3	3.6	7
27	Lipoprotein apheresis in the treatment of dyslipidaemia - the Czech Republic experience. <i>Physiological Research</i> , 2017 , 66, S91-S100	2.1	4
26	Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre. <i>Cardiology Journal</i> , 2019 , 26, 669-679	1.4	7
25	Molecular Genetics and Clinical Features of Japanese Patients with Familial Hypercholesterolemia. 2000 , 39-43		
24	The Steps Beyond Diet and Drug Therapy for Severe Hypercholesterolemia. 2007 , 555-566		
23	Familial Hypercholesterolemia and Lipid Apheresis. 2007 , 267-289		1
22	Low-Density Lipoprotein Apheresis. 2009 , 363-375		1
21	Exchange Transfusion and Haemapheresis. 764-799		
20	LDL-Apheresis Therapy for Refractory Familial Hypercholesterolemia. 2015 , 383-387		
19	????????????????????PCSK9??????. <i>Journal of JCS Cardiologists</i> , 2017 , 25, 145-149	0.1	
18	OBSOLETE: Familial Hypercholesterolemia. 2018 ,		
17	LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW. <i>Russian Journal of Cardiology</i> , 2018 , 74-78	1.3	
16	Introduction de la plasmaphérese comme seul traitement efficace des hypercholestérolémies maximales et redoutables : telles les Hypercholestérolémies familiales homozygotes, ou d'autre origine non élucidée, mais réfractaires à tous les traitements classiques connus jusqu'au [?] <i>Bulletin De L'Académie Nationale De Médecine</i> , 2018 , 202, 1681-1699	0.1	
15	Management of Homozygous Familial Hypercholesterolemia. <i>Contemporary Cardiology</i> , 2021 , 383-404	0.1	
14	Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. <i>Global Cardiology Science & Practice</i> , 2020 , 2020, e202039	0.7	1
13	Lipoprotein aferezi homozigot aileli hiperkolesterolemi hastalarında ventriküler repolarizasyonu etkiler. <i>Turkish Journal of Clinics and Laboratory</i> ,	0	
12	Low-density lipoprotein apheresis: an evidence-based analysis. <i>Ontario Health Technology Assessment Series</i> , 2007 , 7, 1-101	3.1	4
11	Stellenwert der Statine: Nach wie vor die erste Wahl.		

10	Vascular Access in Therapeutic Apheresis: One Size Does not Fit All.. <i>Therapeutic Apheresis and Dialysis</i> , 2022 ,	1.9	1
9	Health-related quality of life in homozygous familial hypercholesterolemia: A systematic review and meta-analysis.. <i>Journal of Clinical Lipidology</i> , 2021 ,	4.9	0
8	Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia.. <i>BMC Pediatrics</i> , 2022 , 22, 131	2.6	0
7	Pharmacotherapy in Familial Hypercholesterolemia- Current State and Emerging Paradigms.. <i>Trends in Cardiovascular Medicine</i> , 2021 ,	6.9	
6	Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: a systematic review and meta-analysis.. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	2
5	COVID-19 and Therapeutic Apheresis. 2022 , 54, 571-577		0
4	Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia.		0
3	Apheresis: What Should a Clinician Know?.		0
2	State of the Art: Lipoproteinapherese. 2023 , 148, e44-e54		0
1	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice [Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. 2023 , 38, 77-278		0